Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JCT (Janction) fluctuated by 69.6% within 24 hours: Trading volume surge and futures activity drive speculative rebound

JCT (Janction) fluctuated by 69.6% within 24 hours: Trading volume surge and futures activity drive speculative rebound

Bitget PulseBitget Pulse2026/04/04 11:51
Show original
By:Bitget Pulse

Volatility Brief

In the past 24 hours, JCT price rebounded from a low of $0.002305 to a high of $0.00382, currently at $0.003669, with a price fluctuation of 69.6% and an increase of about 58.73%. The 24-hour trading volume surged to $57.61 million, market capitalization is around $42.17 million, with a circulating supply of 1.149 billion tokens.

Analysis of the Cause of the Abnormal Movement

• Significant Expansion in Trading Volume: In 24 hours, trading volume soared from the usual several million dollars to $20.7-57.6 million, driving intense price volatility.

• Active Futures Market: Binance futures recorded a 10.26%-13.54% price surge with high trading volume, and total liquidations of about $75,200, leading to a leveraged trading amplification effect.

No official announcements or on-chain reports of large whale transactions; mainly driven by speculative trading of micro-cap tokens.

Market View and Outlook

The mainstream market sentiment is optimistic, with 57% bullish according to the CoinGecko community. X platform discussions focus on JCT's potential as the computing layer infrastructure of the Jasmy ecosystem. Analysts highlight high volatility and no clear catalysts, suggesting to wait for confirmation signals and avoid leveraged risks.

Note: This analysis is generated automatically by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23